Videos

On the latest Lungcast, Kalhan reviewed a 2018 paper he and colleagues penned on the need to establish phenotypes of chronic lung disease progression—such as what cardiology has done with LDL-C for heart attacks.

In the latest Lungcast, a pair of experts considered the marriage of low-dose CT scanning and machine learning to optimize lung disease interception.

The current pox virus outbreak has become closely synonymous with fewer lesions than past mpox—but dermatology guidance is needed all the same.

Symptoms including vestibular rashes and COVID toes have become less synonymous with SARS-CoV-2 infection. Why is that?

As the pandemic passes its third year, one dermatologist foresees their field's own pursuit of specialty-specific vaccination guidelines.

Pediatric dermatologist Mercedes Gonzalez, MD, discusses the new phase 3 B-SIMPLE data supporting berdazimer gel as the first potential molluscum treatment.

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

Recent data during ECCO 23 show ustekinumab results in higher rates of clinical remission and clinical response in patients with inflammatory bowel disease.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

Much of the recent focus on drug development in IBD has centered on the IL-23 pathway.

David Tom Cooke, MD, reviewed the importance of shared decision making as it relates to risk and benefit of cancer screening, as well as in more refined invasive care options.

The connection between different ADHD subtypes and mood disorders has not been fully explored.

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Michael J. Ackerman, MD, PhD, discusses the simplicity and availability of education around CPR and defibrillator use, and the role of clinicians in raising public health preparedness.

A Mayo Clinic cardiologist discusses the national variability in CPR and AED access, and the actions that saved Hamlin's life during Monday Night Football.

A maternal-fetal medicine physician discusses plans for improvements in 2023.

With the population aging, there is a need for new treatments in nephrology.

A continued discussion with Dr. Bays on anti-obesity therapies down the line and where they might be in the near future.

Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.

American Lung Association's Jennifer Folkenroth discusses the issues with "cold turkey," and what every habitual smoker should look for in a cessation plan.